Nmn

2023 in review: NPA on the need for advocates, battling cancerous policy, FDA's reorg, and more

19-Dec-2023 By Daniel Fabricant, PhD, President & CEO, Natural Products Association

It's become too commonplace and cliché to state that the world is very different now than it was just a few years ago. Heck, 2023 is very different at the end than how it began.

NPA’s Fabricant on NMN, 25-(OH)D, NDIs, and more

31-Oct-2023 By Stephen Daniells

While uncertainty continues around NMN, FDA should make it clear to commercial platforms that they haven’t made a final decision on the ingredient and that it should be still available to consumers, says Daniel Fabricant, President & CEO of the Natural...

NPA’s Fabricant on NMN: ‘Taking FDA to Federal Court is expensive, but I don’t see another option’

12-Sep-2023 By Stephen Daniells

The US Food and Drug Administration (FDA) has been unable to reach a decision on the requests made in a Citizen Petition about NMN due to “competing agency priorities”, a response that threatens the NMN sector, says Daniel Fabricant, PhD.

FDA rejects Congressional calls for public hearing on NMN

20-Jul-2023 By Stephen Daniells

The FDA has declined a request from South Carolina Congressman Jeff Duncan for a public hearing on NMN – nicotinamide mononucleotide – in dietary supplements.

NPA’s Fabricant on FDA reorg, HSAs/FSAs, Master Files, NMN and more

07-Jul-2023 By Stephen Daniells

From a proposed reorganization of the Food & Drug Administration to progress (or not) on the NMN situation, there’s a lot going on in the dietary supplements industry. We caught up with Daniel Fabricant, PhD, president and CEO of the Natural Products...

HSA, FSA for supplements: ‘We are about to get the legislation introduced,’ says CRN’s Mister

05-Jul-2023 By Stephen Daniells

The ability for consumers to use pre-tax dollars for healthcare related expenses to purchase dietary supplements may be edging closer as legislation is about to be introduced in Congress to expand eligibility of dietary supplements in HSA and FSA accounts.

CRN’s citizen petition makes case for dietary supplements, drugs to coexist

11-May-2023 By Danielle Masterson

“This is about certainty for supplement companies and access and certainty for consumers.”

ODSP’s director on NDIs, MPL, and NMN

27-Apr-2023 By Danielle Masterson

NutraIngredients-USA caught up with Cara Welch, PhD, Director of FDA's Office of Dietary Supplement Programs. Welch talked inspections, made the case for MPL and hinted NDI guidance is on the way.

Lawsuit against FDA on NMN ‘certainly being considered’, says NPA CEO

14-Mar-2023 By Stephen Daniells

The Natural Products Association is hoping the US Food & Drug Administration is responsive to its recent Citizen’s Petition on the status of NMN, but if it’s not then other options are being considered, Dr Daniel Fabricant, NPA’s CEO tells NutraIngredients-USA.

‘Here we go again’: NPA and ANH file Citizen’s Petition with FDA for NMN relief

07-Mar-2023 By Stephen Daniells

A new Citizen’s Petition is requesting the FDA reevaluate the status of NMN or exercise Enforcement Discretion on the Drug Exclusion Clause for the ingredient.

Amazon removing NMN dietary supplements, citing FDA actions

16-Feb-2023 By Stephen Daniells

The online retail giant has moved to remove supplements containing NMN, an anti-aging ingredient, from its platform following an FDA announcement that NMN is not a legal dietary ingredient.

NPA's Fabricant on CBD, State-led regulations, and NMN's dangerous precedent

31-Jan-2023 By Stephen Daniells

2023 may be a New Year, but many of the old issues for the dietary supplements industry remain. In this wide-ranging interview with Daniel Fabricant, PhD, CEO of the Natural Products Association, we dug into some of the most front-of-mind issues for this...

Guest Article: NPA Chief on 2022’s industry sagas and what these mean for 2023

20-Dec-2022 By Daniel Fabricant, PhD. President & CEO, the Natural Products Association (NPA)

As social creatures were often reluctant to pick sides. It feels personal that we’re picking one person or group of people over another. However, for our industry, the reality is that there are divisive issues.

FDA’s takedown of NMN raises fairness, transparency concerns

15-Nov-2022 By Hank Schultz

NMN, an anti-aging ingredient, has been disallowed by FDA because of its prior investigation as a drug. The determination, which came as something of a surprise given the ingredient’s market history, has raised questions of fairness and transparency.

Potential for sarcopenia? Mitsubishi-funded trial shows NMN intake improves motor function in older men

11-Jul-2022 By Tingmin Koe

A 12-week RCT funded by Mitsubishi Corporation Life Sciences has shown that nicotinamide mononucleotide (NMN) intake has significantly improved certain aspects of muscle mobility, especially gait speed and left grip strength – which the company says presents...

Science shorts: NAD+, NMN, vitamin E in the spotlight

10-Jun-2022 By Tingmin Koe

This round-up of new scientific findings will look at how low NAD+ level is associated with anaemia in women, Mitsubishi Life Sciences’ NMN clinical study findings, and the benefits of vitamin E for exercise recovery and PCOS.

Editor's Spotlight: Startup Focus

Biohacking startup rolls out higher doses for better efficacy and value

15-Nov-2021 By Nikki Hancocks

A biohacking supplements startup which has gone global within two years is aiming to bring more transparency, effective doses, and value for money to the wider anti-ageing supplements sector.

Cellular aging category heats up with new NMN product launch

23-Jun-2021 By Stephen Daniells

Developed in collaboration with scientists at the Buck Institute for Research on Aging, the new product called Elevant Prime is formulated with nicotinamide mononucleotide (NMN).

NMN momentum: GNC China launches supplement this month, clinical trials in progress

14-Dec-2020 By Tingmin Koe

GNC China has launched its first nicotinamide mononucleotide (NMN) supplement this month, after researching and developing the product for the past year.